-
Using a self-developed AI platform, it takes only 10 weeks from the discovery of the anticancer drug targets to the discovery and synthesis of new compounds.
-
Proven capabilities for NCE compound discovery and design, and the establishment of a R&D center(iDear Center) to continuously develop patented substances.
Deargen, a company specializing in the development of novel NCE d**** using artificial intelligence, announced on the 22rd that it had discovered and synthesized a new anticancer target compound using its own AI platform and had already applied for a patent for it.
Deargen has the technology to predict candidates for a novel drug without the 3D structure data of proteins. Deargen’s technology, which uses amino acid sequence data rather than the structure information of proteins, possesses global-level differentiated artificial intelligence technology that enables the rapid development of novel d**** even for proteins whose 3D structure has not yet been identified.
An official from Deargen said : “The new compound for which we have applied for a patent this time is a first-in-class candidate, and we plan to develop a therapeutic agent targeting triple-negative breast cancer (TNBC). TNBC is an area where there are few novel d**** available and it is difficult to find innovative targets, so it is a disease with a high demand for new therapeutics…Deargen confirmed the efficacy of the new compound discovered through in-vitro experiments.”
Top iTechnology Cloud News: Olivia from Paradox Now an SAP Endorsed App Available on SAP Store
Also, the substance that Deargen discovered through this study is an NCE (New Chemical Entity). An NCE refers to a new chemically synthesized drug, which requires a great deal of time and money because it is difficult to develop such a drug that has not been previously approved by the FDA. However, it is within an area with high needs by many global pharmaceutical companies as it has the advantage of being able to receive market monopoly rights for 5 years in the U.S. and 10 years in Europe after product approval.
In particular, Deargen’s achievements are significant in that it discovered the new compound in a shorter time than the existing novel drug discovery process through its collaboration of advanced AI and in-house experts for novel drug development. The target discovery and substance design process, which usually takes about 3 to 4 years in the existing traditional drug development process, was carried out in just 10 weeks, and it took merely 2 weeks for target discovery and 8 weeks for substance design and synthesis.
Currently, Deargen is establishing a large-scale R&D center (iDear Center). With this R&D center, the plan is to further shorten the period of the discovery of candidates by efficiently managing the time required for designing and synthesizing substances. The R&D center will be in charge of fast verification of substances by conducting the design and synthesis verification of substances under joint research with Deargen’s internal pipeline, along with the production of high-quality data.
Daniel Bae, Chief Business Officer of Deargen said : “We plan to continuously derive new substances with patentability through our synthesis research center (iDear Center), which will be established in the first half of next year. We plan to not only build our own pipeline centered on anticancer d****, but also to introduce various business models with our partners that go beyond the existing joint research contracts.” He also said, “Deargen plans to establish its position among global AI drug developers as a company specializing in NCE drug development, from target discovery to compound design and synthesis.”
Top iTechnology Cybersecurity News: Ordr Successfully Achieves SOC 2 Type 2 Compliance
[To share your insights with us, please write to sghosh@martechseries.com]
